RETAINRecruiting

Observational Study on Treatment Adherence and Tolerability of Acalabrutinib (Drug) in Chronic Lymphocytic Leukemia (CLL)

Gender
Women and men
Age
18–99 years
Trial type
Observational
Line of therapy
all
Phase
—

What is this trial about?

is treated, among other things, with acalabrutinib, a drug in the BTK inhibitor class that targets a specific protein (BTK) in CLL cells. It is already approved for the treatment of CLL. The goal of the RETAIN study is to investigate to acalabrutinib—that is, how long treatment is continued—and to gather additional data on tolerability and side effects. Women and men aged 18 and older with CLL who are about to start treatment with acalabrutinib or have recently started it (within the last 28 days) are eligible to participate in the study. The study is not testing a new drug or a new treatment.

Detailed description

Chronic lymphocytic leukemia (CLL) is a form of blood cancer characterized by the uncontrolled proliferation of (a type of white blood cell). Treatment is usually not started until symptoms appear. The choice of medications depends on the patient’s overall health, comorbidities, and the characteristics of the CLL cells. Modern therapy includes drugs that specifically target certain structures in the malignant CLL cells. These include, among others, Bruton’s (BTK inhibitors) such as acalabrutinib. This medication is already approved for the treatment of CLL.

The goal of the RETAIN study is to investigate how long patients continue treatment with acalabrutinib—in other words, to assess treatment adherence. At the same time, the study aims to collect additional data on tolerability, efficacy, and safety. Data will be collected for up to 40 months after the start of treatment with acalabrutinib. The primary focus of the study is treatment adherence after one year—that is, how many patients are still being treated with acalabrutinib and how many have discontinued treatment (e.g., due to side effects or disease progression) (). The study is purely observational and does not test a new treatment. Consequently, the study is not ; that is, both the patient and the doctor are aware that acalabrutinib is being taken.

Women and men aged 18 and older with chronic lymphocytic leukemia (CLL) who are starting or have recently started (within the past 28 days) treatment with acalabrutinib for their CLL are eligible to participate in the study. Acalabrutinib can be used either as (alone or in combination with ) or as second-line or subsequent therapy (after at least one prior line of therapy). If disease progression occurred during a previous BTK inhibitor treatment, patients are not eligible to participate in this study (however, discontinuation due to intolerance is not a reason for exclusion).

Facts

  1. Disease: .
  2. Cancer characteristics: Treatment with acalabrutinib is being initiated or has recently begun (within the last 28 days).
  3. What the study investigates: Safety, efficacy, and, in particular, adherence to acalabrutinib in everyday clinical practice.
  4. Study objective: To collect additional data on acalabrutinib in routine clinical practice, particularly regarding how long treatment is continued.
  5. How long will the study last: initially 1 year, with for up to 40 months.
  6. Study characteristics: (); no testing of new drugs or treatments (non-interventional).

Trial sites

8 trial sites in Germany are listed. Find a site near you.

  • Klinikum St. Marien Amberg

    Mariahilfbergweg 7, 92224 Amberg, Oberpfalz

    Active, not recruiting
  • Ambulantes Krebszentrum Süd, Zweigpraxis des Endokrinologikum Frankfurt

    Frankfurt

    Active, not recruiting
  • Sana Klinikum Hof GmbH

    Eppenreuther Straße 9, 95032 Hof, Saale

    Active, not recruiting
  • Klinikum Aschaffenburg-Alzenau gemeinnützige GmbH

    Active, not recruiting
  • Klinikum Kulmbach

    Recruiting
  • MVZ Weiden

    Recruiting

This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time. Last checked against the trial registers on .

Medical editorial team

  • Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
  • PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine

This description is based on the public trial registry entry and was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.